The new guidelines focus on referral and assessment, treatment, relapse and re-evaluation, and possible endovascular interventions. Regular follow-up and monitoring should be based on symptoms, clinical findings, and acute phase markers.
The EULAR RheumaFacts project reveals large disparities in workforce density, non-pharmacological care availability, and access to modern treatments such as biologics. The study aims to drive policy and advocacy for improving the quality of life of people with rheumatoid arthritis and other RMDs.
A new approach to managing fatigue in inflammatory arthritis combines physical activity and cognitive behavioral techniques. Digital patient education is shown to be cost-effective and efficient in improving patient outcomes. Caregiver-focused interventions are also crucial in supporting daily functioning and disease management.
A new study presented at EULAR 2026 highlights the importance of structured cardiac evaluation in systemic sclerosis, particularly for patients with multi-system disease. The research also identified PDE4B as a promising therapeutic target across various tissues and cell subsets, offering potential benefits for patients with early dise...
A multidisciplinary patient organisation provides accessible, person-centred support through professional counselling, offering a non-clinical setting to discuss everyday challenges and work-related issues. The service also offers unique insights into unmet needs, such as medication shortages and administrative barriers.
Researchers present findings on a novel therapeutic strategy for PsA, using synovial biopsy-driven treatment with biologics targeting IL-17/23 axis. A separate study evaluates the effectiveness of personalized dietary interventions in improving clinical outcomes.
A population-based cohort study found that IIM subtypes differ in incidence, particularly by sex and ethnicity. Automated quantitative nailfold videocapillaroscopy (NVC) model shows superior discriminative capacity for predicting disease activity compared to traditional serum biomarkers.
New AI algorithms demonstrate improved accuracy in evaluating radiographic data and assessing joint inflammation. These innovations include the RADAR algorithm, ADMIRA, and thermography-based systems, offering promising alternatives to traditional imaging methods.
The updated ASAS-SPARTAN revised classification criteria for axSpA prioritize MRI of the sacroiliac joints and incorporate a focused set of clinical variables. The new recommendations also emphasize the role of imaging in diagnosing and managing both axial and peripheral SpA.
A new study suggests that adding low-dose glucocorticoids to maintenance treatment for ANCA-associated vasculitis (AAV) does not reduce the risk of major flares, but is associated with an increased risk of chronic damage and hospitalization. In contrast, rituximab use was linked to a lower risk of major flares.
Researchers have developed operational definitions of srSLE based on disease activity and treatment exposure, showing strong predictive performance. A novel autoantibody signature has also been identified to predict atherosclerosis progression in juvenile-onset systemic lupus erythematosus
The study evaluated digital platforms and AI chatbots for improving health literacy in patients with RMDs. The results showed high usability, perceived usefulness, and trust among participants, suggesting a promising approach to patient education.
A new study using the EUSTAR database found that patients with active disease at baseline had higher cumulative incidence rates of organ and multi-system involvement. Early disease activity monitoring is crucial for identifying patients at risk, guiding treatment decisions, and improving patient outcomes.
Comorbidities such as cardiovascular disease, cognitive impairment, and osteoporotic fractures are common in RMD patients. Systemic autoimmune diseases increase the risk of cardiac arrhythmias and mortality. PPI use is linked to a higher risk of major osteoporotic fractures, while JAKi therapy may pose a risk of venous thromboembolism.
A study found that patients continuing ULT remained flare-free for longer over 24 months, with a cumulative flare incidence of 12.3% compared to 31.8% in the ULT discontinuation attempt group. Effective weight management and exercise are key to managing gout and rheumatoid arthritis.
Research studies reveal suboptimal adherence to treat-to-target strategies in rheumatoid arthritis, with lower rates among spondyloarthritis patients. Additionally, data from registries show the potential benefits of glucagon-like peptide-1 receptor agonists for weight loss and disease activity management in RMD.
Researchers present results from Phase 1 trials of CAR-T cell therapies in patients with refractory rheumatoid arthritis and systemic sclerosis, showing improved disease activity and clinical remission. The findings suggest an immunological 'reset' strategy may offer true curative potential for these severe diseases.
The EULAR recommends a multidisciplinary approach to managing Behçet's syndrome, aiming to prevent irreversible organ damage and maximize quality of life. The updated guidelines prioritize monoclonal TNFi for patients with eye, vascular, or nervous system involvement, promoting earlier recognition and more consistent care.
The 2025 update provides 5 overarching principles and 9 individual recommendations for managing rheumatoid arthritis, emphasizing patient-centered care and simplifying clinical approaches. The update prioritizes treatment targets, monitoring frequency, and the role of methotrexate, glucocorticoids, biologics, and JAK inhibitors.
The European Alliance of Associations for Rheumatology (EULAR) has introduced three overarching principles and 11 points to consider for assessing disease activity in AOSD. The guidelines emphasize the importance of adopting a valid, reliable, and easily transferable definition of disease activity, which includes fever, skin rash, arth...
The European Alliance of Associations for Rheumatology has developed a new disease activity score (EAPSDAS) to assess clinical manifestations in antiphospholipid syndrome (APS). The score evaluates thrombotic, obstetric, microvascular, and non-thrombotic symptoms, providing insights into disease activity and treatment response.
Researchers developed a points-based classification model using eight variables to assess joint pain, genetic mutations, and iron loading. The criteria show promise in diagnosing haemochromatosis arthropathy with high specificity and sensitivity, paving the way for new treatment options.
The European Alliance of Associations for Rheumatology (EULAR) is hosting the EULAR 2026 Congress in London, featuring a scientific program with new clinical data and updated treatment guidelines. The congress will also provide exclusive media opportunities, including a press conference and one-on-one interviews with expert panelists.
EULAR has established new points to consider and consensus definitions for managing difficult-to-treat psoriatic arthritis, aiming to improve treatment options and care for patients. The guidelines focus on identifying the biology behind treatment non-response and promote personalized treatment approaches.
The new guidelines focus on the role of kidney biopsy, combination immunosuppressive treatment, and kidney protective drugs to prevent chronic kidney disease progression. They also address specific guidance for patients with renal response versus those with persistently active or relapsing disease.
The EWRR Congress will become an integral part of EULAR's meeting portfolio from 2027 onwards. The event aims to attract young scientists and provide opportunities for networking and collaboration.
The new guidelines provide evidence-based recommendations for patient management, identifying high-risk individuals and enhancing outcomes. The guidelines address specific ILD management algorithms for underlying rheumatic diseases, supporting comprehensive care for patients with CTD-ILD.
The European Alliance of Associations for Rheumatology (EULAR) journal Annals of the Rheumatic Diseases (ARD) has achieved a notable increase in its impact factor to 20.6, surpassing 58 other titles in rheumatology and reaffirming its status as the leading journal for original research in both basic and clinical fields. This recognitio...
Recent studies suggest that early biologics in severe psoriatic arthritis may not significantly benefit patients compared to standard step-up care with methotrexate. However, a study found that intensive therapy with early biologics or combination csDMARDs can rapidly control disease activity and maintain better outcomes at 1 year.
The recombinant zoster vaccine was found to be well-tolerated in patients with inflammatory rheumatic musculoskeletal diseases, with only a few reports of flare and serious AEs. The majority of patients tolerated the vaccine without significant adverse events.
The European Alliance of Associations for Rheumatology (EULAR) has released a set of points-to-consider on the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancer. The guidance aims to help healthcare teams manage treatment decisions while balancing risks and benefits.
Young people with juvenile rheumatoid diseases (jRMDs) often struggle to manage their condition into adulthood, leading to worse disease outcomes. EULAR's new guidelines aim to enhance knowledge and health literacy through personalized support, promoting long-lasting behavioral changes.
Prof. Annamaria Iagnocco's election to the BioMedical Alliance Europe board highlights her expertise in rheumatology and medical education. The board plays a crucial role in shaping policies supporting biomedical research and patient access to innovative treatments.
The EULAR 2025 Congress in Barcelona will feature pioneering research, clinical advancements, and patient-centred innovations in rheumatology. Accredited press representatives will have access to exclusive interview opportunities with key speakers.
The new guidelines aim to unify the diagnosis and management of children and adults with Still's disease, previously separated by age. The recommendations emphasize shared decision-making between patients and treating teams, and prioritize achieving drug-free remission through treat-to-target strategies.
The new criteria classify hand osteoarthritis based on age, morning stiffness duration, and joint features. Researchers can now apply the criteria in large studies without additional clinical joint examinations.
The European Alliance of Associations for Rheumatology (EULAR) has introduced new guidelines for imaging in the diagnosis and management of crystal-induced arthropathies. The recommendations prioritize patient-centered care, emphasizing the importance of medical history, laboratory results, and physical examination alongside imaging fi...
The European Alliance of Associations for Rheumatology (EULAR) has developed new recommendations for managing fatigue in people with inflammatory rheumatic and musculoskeletal diseases. The guidelines emphasize the importance of monitoring fatigue and offering management options based on a shared decision between patients and healthcar...
The updated EULAR recommendations for managing SLE emphasize individualized, multidisciplinary care and consider patient education and societal costs. Non-pharmacological interventions and careful drug selection based on disease type and severity are also key to improving long-term outcomes.
The updated antiphospholipid syndrome (APS) classification criteria offer improved sensitivity and specificity, allowing for risk-stratified epidemiologic studies and clinical trials. The new system specifies an entry criterion of at least one positive aPL test within 3 years of clinical criterion identification.
The European Alliance of Associations for Rheumatology (EULAR) has developed new standards for postgraduate rheumatology training, setting out 28 competencies across seven domains. These include medical expertise, diagnosis and management of individual diseases, and effective communication with patients and colleagues.
The new EULAR points-to-consider support individuals with rheumatic and musculoskeletal diseases (RMDs) by acknowledging the benefits of staying in work, including increased self-worth and financial independence. These principles aim to optimise work-life balance and support physical and mental health.
EULAR has updated its COVID-19 vaccination recommendations for people with rheumatic and musculoskeletal diseases, based on emerging evidence and expert opinion. The new guidelines emphasize the importance of vaccination in preventing infection and improving outcomes.
The European Alliance of Associations for Rheumatology (EULAR) has published guidelines for analyzing safety and effectiveness of new therapies using observational data. The guidelines aim to increase trustworthiness of results gained from observational data.
A registry study found that people with inflammatory RMDs, such as rheumatoid arthritis and psoriatic arthritis, tolerate their COVID vaccine well, with short-lived reactions being the most common side effect. The majority of participants were able to continue on their normal medication with no changes.
The European Alliance of Associations for Rheumatology (EULAR) has updated its points to consider on the use of immunomodulatory drugs in severe COVID-19 treatment. The new guidelines focus on repurposing rheumatology drugs, with WHO recommending dexamethasone and anti-IL-6 receptor antibodies for treatment.
The new EULAR consensus provides guidance for investigating treatments in people at risk of RA. The guidelines recommend considering subclinical inflammation, clinical arthritis, or progression to RA as study endpoints across trials.
The European Alliance of Associations for Rheumatology has developed guidelines for studies on work participation in people with inflammatory arthritis. The guidelines focus on identifying contextual factors and accounting for changes in work status over time.
EULAR taskforce develops guidelines to standardize intra-articular injection (IAT) care, emphasizing patient-centered outcomes and contextual factors. The new recommendations aim to improve IAT quality, providing patients with personalized information and support.
The European Alliance of Associations for Rheumatology taskforce provides guidelines for treating severe COVID-19 with immunomodulatory therapies. The recommendations consider the individual's condition and stage of the disease, including antiviral medicines, oxygen therapy, and anticoagulation.